Table 2 Antimicrobial strategies used for microbiologically confirmed CAP episodes that received broad-spectrum antimicrobial therapy
CRB65 0–1 | CRB65 2 | CRB65 3–4 | All groups | |
|---|---|---|---|---|
n | 88 | 35 | 11 | 134 |
Strategy instituted at point of AMS reporting | ||||
Broad-spectrum to narrow-spectrum B-lactam transition | 28,4% | 20,0% | 9,1% | 24,6% |
Transition not recommended | 6,8% | 8,6% | 27,3% | 9,0% |
Transition feasible, but continued broad-spectrum antimicrobial | 64,8% | 71,4% | 63,6% | 66,4% |
Administration form instituted at point of AMS reporting | ||||
Intravenous to oral conversion | 20,5% | 14,3% | 0,0% | 17,2% |
Conversion not possible | 11,4% | 17,1% | 45,5% | 15,7% |
Conversion possible, but not performed | 68,2% | 68,6% | 54,5% | 67,2% |